NCT07476326
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07476326
Title Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Biocon Biologics UK PLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries TUR | ROU | ESP


No variant requirements are available.